VIE Viela Bio Inc.

35.61
-3.2  -8%
Previous Close 38.81
Open 36.97
Price To Book 5.12
Market Cap 1,815,780,608
Shares 50,990,750
Volume 94,892
Short Ratio
Av. Daily Volume 92,525
Stock charts supplied by TradingView

NewsSee all news

  1. Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

    GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today reported financial

  2. Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020

    GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today announced it will host a

  3. Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren's Syndrome

    GAITHERSBURG, Md., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced that the first

  4. Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights

    GAITHERSBURG, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today reported financial

  5. Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions

    Viela Bio is eligible to receive an upfront licensing fee of $30 million as well as development and commercialization milestones and payments based, in part, on sales revenue GAITHERSBURG, M.D., Oct. 09, 2019 (GLOBE

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date June 11, 2020.
Inebilizumab
Neuromyelitis Optica Spectrum Disorder
Phase 2 trial to be initiated 4Q 2019.
Inebilizumab
Kidney transplant desensitization
Phase 3 trial to be initiated mid-2020.
Inebilizumab
Myasthenia gravis
Phase 2b trial initiation announced December 11, 2019.
VIB4920
Sjögren’s syndrome
Phase 2a trial initiated October 2019.
VIB4920
Kidney transplant rejection
Phase 1b interim data due 2Q 2020.
VIB7734
Cutaneous lupus erythematosus
Phase 2b trial to be initiated mid-2020.
Inebilizumab
IgG4-related disease

Latest News

  1. Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

    GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today reported financial

  2. Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020

    GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today announced it will host a

  3. Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren's Syndrome

    GAITHERSBURG, Md., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced that the first

  4. Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights

    GAITHERSBURG, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today reported financial

  5. Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions

    Viela Bio is eligible to receive an upfront licensing fee of $30 million as well as development and commercialization milestones and payments based, in part, on sales revenue GAITHERSBURG, M.D., Oct. 09, 2019 (GLOBE

  6. Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the